Biomea Fusion reports Phase II COVALENT-111 data showing 1% HbA1c reduction at Week 52 with icovamenib in type 2 diabetes patients

Reuters03-14 16:30

<a href="https://laohu8.com/S/BMEA">Biomea Fusion</a> reports Phase II COVALENT-111 data showing 1% HbA1c reduction at Week 52 with icovamenib in type 2 diabetes patients

Biomea reported 52-week follow-up results from the Phase II COVALENT-111 trial of icovamenib in adults with type 2 diabetes at the ATTD conference. The double-blind, randomized, placebo-controlled study tested 100 mg once daily for 8 weeks, 100 mg once daily for 12 weeks, or 8 weeks once daily followed by 4 weeks twice daily. In severe insulin-deficient diabetes patients, the 12-week once-daily arm showed a mean HbA1c reduction of 1.5% at Week 52 versus placebo. In participants on GLP-1-based therapy at entry, icovamenib was associated with a 1.2% HbA1c reduction at Week 52 versus placebo. Biomea said 52-week follow-up data from type 1 diabetes patients in COVALENT-112 are expected in Q2 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biomea Fusion Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603140430PRIMZONEFULLFEED9672005) on March 14, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2619484123?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-14 16:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2619484123","market":"nz","top_or_hot":-1,"title":"Biomea Fusion reports Phase II COVALENT-111 data showing 1% HbA1c reduction at Week 52 with icovamenib in type 2 diabetes patients","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/BMEA\">Biomea Fusion</a> reports Phase II COVALENT-111 data showing 1% HbA1c reduction at Week 52 with icovamenib in type 2 diabetes patients\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Biomea reported 52-week follow-up results from the Phase II COVALENT-111 trial of icovamenib in adults with type 2 diabetes at the ATTD conference. The double-blind, randomized, placebo-controlled study tested 100 mg once daily for 8 weeks, 100 mg once daily for 12 weeks, or 8 weeks once daily followed by 4 weeks twice daily. In severe insulin-deficient diabetes patients, the 12-week once-daily arm showed a mean HbA1c reduction of 1.5% at Week 52 versus placebo. In participants on GLP-1-based therapy at entry, icovamenib was associated with a 1.2% HbA1c reduction at Week 52 versus placebo. Biomea said 52-week follow-up data from type 1 diabetes patients in COVALENT-112 are expected in <a href=\"https://laohu8.com/S/QTWO\">Q2</a> 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biomea Fusion Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603140430PRIMZONEFULLFEED9672005) on March 14, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biomea Fusion reports Phase II COVALENT-111 data showing 1% HbA1c reduction at Week 52 with icovamenib in type 2 diabetes patients</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiomea Fusion reports Phase II COVALENT-111 data showing 1% HbA1c reduction at Week 52 with icovamenib in type 2 diabetes patients\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-14 16:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/BMEA\">Biomea Fusion</a> reports Phase II COVALENT-111 data showing 1% HbA1c reduction at Week 52 with icovamenib in type 2 diabetes patients\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Biomea reported 52-week follow-up results from the Phase II COVALENT-111 trial of icovamenib in adults with type 2 diabetes at the ATTD conference. The double-blind, randomized, placebo-controlled study tested 100 mg once daily for 8 weeks, 100 mg once daily for 12 weeks, or 8 weeks once daily followed by 4 weeks twice daily. In severe insulin-deficient diabetes patients, the 12-week once-daily arm showed a mean HbA1c reduction of 1.5% at Week 52 versus placebo. In participants on GLP-1-based therapy at entry, icovamenib was associated with a 1.2% HbA1c reduction at Week 52 versus placebo. Biomea said 52-week follow-up data from type 1 diabetes patients in COVALENT-112 are expected in <a href=\"https://laohu8.com/S/QTWO\">Q2</a> 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biomea Fusion Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603140430PRIMZONEFULLFEED9672005) on March 14, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SG9999014013.SGD","symbol_name":"United Global Durable Equities Fund Dis SGD","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260314:nNDLb55NNH:1","article_id":"2619484123","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2619484123","pubTimestamp":1773477016,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Biomea Fusion reports Phase II COVALENT-111 data showing 1% HbA1c reduction at Week 52 with icovamenib in type 2 diabetes patients. Biomea reported 52-week follow-up results from the Phase II COVALENT-111 trial of icovamenib in adults with type 2 diabetes at the ATTD conference. The double-blind, randomized, placebo-controlled study tested 100 mg once daily for 8 weeks, 100 mg once daily for 12 weeks, or 8 weeks once daily followed by 4 weeks twice daily. In severe insulin-deficient diabetes patients, the 12-week once-daily arm showed a mean HbA1c reduction of 1.5% at Week 52 versus placebo. In participants on GLP-1-based therapy at entry, icovamenib was associated with a 1.2% HbA1c reduction at Week 52 versus placebo. Biomea said 52-week follow-up data from type 1 diabetes patients in COVALENT-112 are expected in Q2 2026.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","BK4588":"碎股","BK4112":"金融交易所和数据","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","BK4539":"次新股","BMEA":"Biomea Fusion, Inc.","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","BK4585":"ETF&股票定投概念","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","BK4139":"生物科技","NDAQ":"纳斯达克OMX交易所","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD"},"translate_title":"Biomea Fusion报告II期共价-111数据显示，2型糖尿病患者使用icovamenib治疗第52周时HbA1c降低1%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BMEA":0.9,"NDAQ":0.9},"content_text":"Biomea Fusion reports Phase II COVALENT-111 data showing 1% HbA1c reduction at Week 52 with icovamenib in type 2 diabetes patients\n    \n\n        Biomea reported 52-week follow-up results from the Phase II COVALENT-111 trial of icovamenib in adults with type 2 diabetes at the ATTD conference. The double-blind, randomized, placebo-controlled study tested 100 mg once daily for 8 weeks, 100 mg once daily for 12 weeks, or 8 weeks once daily followed by 4 weeks twice daily. In severe insulin-deficient diabetes patients, the 12-week once-daily arm showed a mean HbA1c reduction of 1.5% at Week 52 versus placebo. In participants on GLP-1-based therapy at entry, icovamenib was associated with a 1.2% HbA1c reduction at Week 52 versus placebo. Biomea said 52-week follow-up data from type 1 diabetes patients in COVALENT-112 are expected in Q2 2026.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biomea Fusion Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603140430PRIMZONEFULLFEED9672005) on March 14, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2619484123","isCrawlerRequest":true}